Norwalk, CT, March 17, 2022 —The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Triumvira Immunologics (“Triumvira”), an Austin, TX-based clinical-stage biotech developing novel, targeted autologous and allogeneic T cell immunotherapies that co-opt the natural biology of T cells to treat solid tumors and blood cancers.
The MIF is joined by other investors, including the B Capital Group and ATEM Capital, with participation from existing Triumvira investors Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. The funding will support Triumvira’s continued preclinical and clinical development of its T cell antigen coupler (TAC)-T cell therapy programs. Triumvira’s proprietary TAC receptor, a multi-domain chimeric molecule, interacts directly with the natural T cell receptor to uniquely help T cells recognize and eliminate tumor cells.
“We are thrilled to partner with Triumvira to help advance its novel (TAC)-T cell therapy programs which could have significant benefit for the treatment of myeloma,” said Michael Andreini, President and CEO of the Multiple Myeloma Research Foundation. “This is the MIF’s eighth investment and with the continued growth of its portfolio, we are strengthening our commitment to unlock the potential of immunotherapies and speed their delivery to each and every myeloma patient.”
“We are excited about our investment in Triumvira and the potential of (TAC)-T cell therapy approaches for hematologic malignancies,” said Peter Kosa, Ph.D., Managing Director of the Myeloma Investment Fund. “This investment is consistent with our mission to drive the development of precision treatments and we believe Triumvira’s technology will have broad applications in treating myeloma.”
For more information, visit www.triumvira.com.
About the Myeloma Investment Fund The Myeloma Investment Fund (MIF), is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to accelerate the delivery of precision medicine approaches and a cure to every multiple myeloma patient. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research, providing access to longstanding relationships with pharmaceutical companies and academic medical centers, a clinical network of 23 sites, and data from the largest genomics data set of any cancer. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit MyelomaInvestmentFund.org.
Media Contact:
C.J. Volpe
Director, PR and Communications
Multiple Myeloma Research Foundation (MMRF)
203.652.0453
[email protected]
